Ireland
--:--IST
Active, not recruiting Phase 3

The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer

NCT04065009 · tracked via the Priya Life Science Sweden tracker
Phase
Phase 3
Started
2020-08-27
Last updated
2026-09-28

Condition(s) studied

Advanced Ovarian Cancer

Investigational drug(s) / intervention(s)

Ropivacaine →Saline Solution

Ropivacaine: Experimental drug will be administered intraperitoneally

Saline Solution: Placebo will be administered intraperitoneally

Study summary

Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour. Radical resection of all tumour visible by the naked eye followed by adjuvant chemotherapy is associated with best chance of prolonged survival. However, because of tumour dissemination in the peritoneal cavity, radical surgery is often very extensive with surgery in all quadrants of the abdomen and multi-organ resection with substantial risk of postoperative severe complications and subsequent delay in administration of adjuvant chemotherapy. Longer time-interval between surgery to start of adjuvant chemotherapy has been associated with decrease in survival.

Surgery presents opportunities not only for eradicating tumours but, paradoxically, also for proliferation and invasion of residual cancer cells. It increases the shedding of malignant cells into the blood and lymphatic circulations, inhibits their apoptosis and potentiates their invasion capacity. Additionally, the immune system, the inflammatory system and the neuroendocrine system react to surgery with important changes, which have been proven to promote progression of cancer. Several anaesthesia-related factors play an important role in perioperative tumorigenesis such as inhalational anaesthetics, opiate analgesics, local anaesthetics and regional anaesthesia, all of which may impact short-term morbidity and long-term mortality. A previous randomized placebo-controlled pilot study suggests that women who receive local anesthetics intraperitoneally preoperatively have a significantly decreased time-interval to initiation of adjuvant chemotherapy.

In a prospective, randomised, multi-centre study, we plan to further assess if intraperitoneal local anaesthetics administered perioperatively during 72 h leads to early start of chemotherapy compared to placebo in patients undergoing cytoreductive surgery for FIGO stage III-IV ovarian cancer.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * ASA I-III * Scheduled for upfront cytoreductive surgery for presumed stage III or IV epithelial ovarian cancer * Signed written informed consent Exclusion Criteria: * Contraindication to epidural anesthesia * Allergy to any component drugs used during epidural or intraperitoneal anesthesia (Ropivacaine, Sufentanil) * Uncontrolled renal, liver, heart failure or ischemic heart disease * Speech, language or cognitive difficulties * Women in whom cytoreductive surgery is not attempted at time of upfront laparotomy due to extent of disease

Primary outcome measure(s)

  • Time-interval from upfront surgery to adjuvant chemotherapy — Number of days to start of adjuvant chemotherapy (0 - 60 days)
    Days from surgery to first infusion of adjuvant chemotherapy

Trial sites (1)

FacilityCityRegionStatus
Karolinska Hospital, Solna Stockholm Sweden
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04065009 on ClinicalTrials.gov ↗ ← All trials in Sweden